

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 June 2003 (05.06.2003)

PCT

(10) International Publication Number
WO 03/045440 A1

(51) International Patent Classification?: **A61K 48/00**,
C12N 15/11, C07K 14/47, A61K 38/16

(21) International Application Number: PCT/SE02/02198

(22) International Filing Date:
28 November 2002 (28.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/333,513 28 November 2001 (28.11.2001) US

(71) Applicant (for all designated States except US): **ANGIO-GENETICS SWEDEN AB** [SE/SE]; Medicinaregatan 7B, S-413 90 Göteborg (SE).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **MAKINO, Yuichi** [JP/JP]; Tokyo (JP). **CAO, Yihai** [SE/SE]; Karolinska Institutet, S-171 77 Stockholm (SE). **POELLINGER, Lorenz** [SE/SE]; Karolinska Institutet, S-171 77 Stockholm (SE).

(74) Agent: **ALBIHNS STOCKHOLM AB**; Box 5581, S-114 85 Stockholm (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: REGULATION OF HYPOXIA-INDUCIBLE GENE EXPRESSION WITH ANTISENSE INHIBITORY PAS DOMAIN PROTEIN



(57) Abstract: A pharmaceutical composition comprises the sequence of SEQ ID NO:s 3-5 or pharmaceutically equivalent sequences. Methods employing the pharmaceutical compositions include treatments to increase angiogenesis, to stimulate HIF-1 α function, to treat hypoxia-related conditions, and to maintain normal cell functions under hypoxia.

WO 03/045440 A1



(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

REGULATION OF HYPOXIA-INDUCIBLE GENE EXPRESSION WITH ANTISENSE INHIBITORY PAS DOMAIN PROTEIN

FIELD OF THE INVENTION

The invention relates generally to the field of proteins related to angiogenic processes. The invention further relates to methods useful for inducing angiogenesis.

BACKGROUND OF THE INVENTION

Angiogenesis is a critical function for normal organism functioning and survival. Insufficient angiogenesis can result in cell or tissue death. Excessive angiogenesis has been linked to tumor development and other undesirable conditions. Some of the genes and biochemical processes involved in angiogenesis have been described. For example, dysregulation or enhanced activation of HIF-1 α function have been implicated in a variety of pathological conditions including induced tumor growth rates^{9,17,18} and inflammatory angiogenesis¹⁹. Since it is important for organisms to maintain normal angiogenesis and for certain cells or tissues to be able to functionally counteract the activated form of HIF-1 α , there remains a need in the art to provide both further information on the mechanisms that underlie angiogenesis and to present new methods useful in either increasing or decreasing angiogenesis.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to present further information related to angiogenesis and to supply novel methods to affect angiogenic responses.

According to a first embodiment of the invention, a pharmaceutical composition is provided which comprises the sequence of SEQ ID NOS:3, 4, 5, sequences complementary to SEQ ID NO:1 or active fragments or analogs thereof. The composition may further comprise pharmaceutical carriers, adjuvants, and diluents.

According to a further embodiment of the invention, methods of increasing angiogenesis, methods of increasing HIF-1 α function, methods of treating a hypoxia-related condition, and methods of maintaining normal cell or tissue function under hypoxic conditions in a cell, a group of cells, or an organism are provided, which

comprise administering a pharmaceutically effective amount of a composition according to the first embodiment to the cell, group of cells, or organism. The hypoxia-related condition may be, for example, ischemia, coronary heart disease, wound healing, stroke, or diabetic ulceration.

According to a further embodiment of the invention, a plasmid is provided comprising the sequence of SEQ ID NOS:3, 4, 5, or sequences complimentary to SEQ ID NO:1. The invention also includes vectors containing such a plasmid and host cells transfected with such a vector.

According to a further embodiment of the invention, a host cell is provided which expresses the protein encoded by any one of SEQ ID NOS:3, 4, or 5.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows the deduced amino acid sequence of mouse IPAS (SEQ ID NO:1);

Figure 1B is a diagram representing a comparison between mouse IPAS, mouse HIF-1 α , and mouse HLF/EPAS1 with percent identities;

Figure 1C shows the results of a RNA blot analysis of IPAS expression in adult mice tissues;

Figure 2 shows the results of an *in situ* hybridization analysis of IPAS expression in selected regions of adult mice, specifically,

Figure 2A shows a light field section of cornea after hybridization with antisense RNA probes of mIPAS;

Figure 2B shows a dark field section of cornea after hybridization with antisense RNA probes of mIPAS;

Figure 2C shows a light field section of cornea after hybridization with antisense RNA probes of mHIF-1 α ;

Figure 2D shows a dark field section of cornea after hybridization with antisense RNA probes of mHIF-1 α ;

Figure 2E shows a light field section of retina after hybridization with antisense RNA probes of mIPAS;

Figure 2F shows a dark field section of retina after hybridization with antisense RNA probes of mIPAS;

Figure 2G shows a light field section of retina after hybridization with antisense RNA

probes of mHIF-1 α ;

Figure 2H shows a dark field section of retina after hybridization with antisense RNA probes of mHIF-1 α ;

Figure 2I shows a light field section of cerebellum after hybridization with antisense RNA probes of mIPAS;

Figure 2J shows a dark field section of cerebellum after hybridization with antisense RNA probes of mIPAS;

Figure 2K shows a light field section of cerebellum after hybridization with antisense RNA probes of mHIF-1 α ;

Figure 2L shows a dark field section of cerebellum after hybridization with antisense RNA probes of mHIF-1 α ;

Figure 3A shows IPAS inhibition of HIF mediated reporter gene activation in hypoxic HeLa cells;

Figure 3B shows IPAS inhibition of HLF/EPAS1 mediated reporter gene activation in hypoxic HeLa cells;

Figure 3C shows that HIF-1 α and HLF protein stability are not affected by IPAS in HeLa cells;

Figure 3D demonstrates hypoxia-inducible gene expression impairment by IPAS overexpressing cells;

Figure 3E shows IPAS inhibition of the DNA binding activity of HIF-1 α , where the asterisk indicates constitutive HRE binding activity, the arrow indicates a HIF-1 α /Arnt-DNA complex, S indicates unlabeled HRE control and NS indicates unrelated sequence control;

Figure 3F shows immunoprecipitation with anti-GST antibodies revealing that GST IPAS physically interacts with *in vitro* translated HIF-1 α ;

Figure 3G represents a coimmunoprecipitation of ³⁵S-labeled IPAS with GAL4-fused HIF-1 α fragments by anti-GAL4 antibodies showing the N-terminus of HIF-1 α mediating heterodimerisation with IPAS;

Figure 3H shows how combinations of *in vitro* translated IPAS, HIF-1 α , Arnt, or control lysate were analyzed to reveal that the IPAS/HIF-1 α heterodimer fails to bind the HRE sequence motif;

Figure 4 shows IPAS expression in hepatoma cells retards tumor growth, specifically,

Figure 4A shows increases in tumor volumes after subcutaneous implantation of wild-type Hepalclc7 or Hepa IPAS cells in immunodeficient SCID mice, where the asterisk indicates ($p < 0.001$) difference in results between the two cell lines and a double asterisk indicates a difference of ($p < 0.01$);

Figure 4B shows vascular density by immunohistochemical staining for CD31 antigen expression

Figure 4C represents a numerical analysis of vascular density with results obtained by counting under a light microscope, where an asterisk indicates ($p < 0.001$) difference between wild-type and cell derived tumors;

Figure 5A shows IPAS expression in primary cultures of mouse cornea epithelium cells using RNA blotting following incubation under normoxic or hypoxic conditions for 24 hours;

Figure 5B shows hypoxia inducible expression of IPAS mRNA in mouse tissues, where the white arrow indicates a 2.0 kb form of β -actin and a black arrow indicates a 1.8 kb form of β -actin;

Figure 5C shows VEGF mRNA expression in hepatoma or primary cornea cells transfected with control or antisense IPAS vectors;

Figure 5D displays photographs of the results of ocular angiogenesis studies wherein polymers containing IPAS antisense or sense oligonucleotides were implanted in to micropockets of the cornea, the area represented by an arrow, showing the antisense oligonucleotides caused neovascularization as indicated by the bracket;

Figure 5E results of ocular angiogenesis studies presenting the mean \pm SD area of neovascularisation, where an asterisk represents a difference of ($p < 0.001$) between the scrambled and sense oligonucleotide treated groups;

Figure 5F is a schematic model of the negative regulation of HIF-1 α function by IPAS; and

Figure 6 shows the full length IPAS DNA sequence (SEQ ID NO:2).

DETAILED DESCRIPTION

Alteration of gene expression is a crucial component of adaptive responses to hypoxia. These responses are mediated by hypoxia-inducible transcription factors (HIFs)^{1,2}. A novel basic helix-loop-helix (bHLH)/PAS protein related to HIFs was

identified by methods detailed below and termed Inhibitory PAS (Per/Arnt/Sim) domain protein, or IPAS. IPAS was found to contain no transactivation function and demonstrated dominant negative regulation of HIF-mediated control of gene expression. Ectopic expression of IPAS in hepatoma cells selectively impaired induction of genes involved in adaptation to a hypoxic environment, notably the vascular endothelial growth factor (VEGF) gene. It also resulted in retarded tumor growth and reduced tumor vascular density in vivo.

IPAS shows predominantly nuclear localization under both normoxic and hypoxic conditions, as assessed by green fluorescent fusion protein assays (data not shown). As described more fully below, IPAS was predominantly expressed in mice in Purkinje cells of the cerebellum and in corneal epithelium of the eye. Expression of IPAS in the cornea correlated with low levels of expression of the VEGF gene under hypoxic conditions. Strikingly, application of an IPAS antisense oligonucleotide to the mouse cornea induced angiogenesis under normoxic conditions, and unmasked hypoxia-dependent induction of VEGF gene expression in hypoxic cornea cells. These unexpected results indicate a novel mechanism for negative regulation of angiogenesis and maintenance of an avascular phenotype.

Example 1: Isolation of IPAS cDNA and Creation of Antisense IPAS Expression Plasmid

Hidden Markov Model profiles³ for HIF homology were built using the HMMER 1.8.3 software²¹ from nucleotide sequences corresponding to the PAS domain of a selected number of bHLH/PAS factors. The model profiles were used to search mouse expressed sequence tag (EST) databases. An EST clone encoding a putative novel protein and containing a bHLH PAS motif was identified (Gene Bank accession # AA028416) and was subsequently obtained, sequenced and designated IPAS.

The nucleotide sequence for IPAS is provided at SEQ ID NO:2 (Fig. 6). DNA sequence analysis revealed that IPAS cDNA contains an open reading frame of 921 nucleotides, encoding a polypeptide of 307 amino acids (Fig. 1A, SEQ ID NO:1). Alignment analysis of the amino acid sequence with known bHLH PAS factors showed high similarity to HIF-1 α ⁴ and HLF/EPAS1^{5,6} in the N-terminal bHLH domain

(75% and 76% identity, respectively; Fig. 1B), and to a lesser extent within the PAS region (34% and 36% in the PAS A, and 40% and 36% in the PAS B domain, respectively; Fig. 1B). Notably, IPAS was found to lack the sequence corresponding to C-terminal region of HIF-1 α and HLF/EPAS1, in which two transactivation domains (N-TAD and C-TAD) have been previously identified (Fig. 1B).

pcDNA3 IPAS was constructed by inserting an *EcoRI*-*Not* I fragment from pT7T3D IPAS (Gene Bank accession # AA028416) into pcDNA3 (Invitrogen). The resulting vector was then used to subclone IPAS into the pCMV FLAG vector²², pGEX-4T-3 (Amersham-Pharmacia Biotech), pCMX GAL4, or pCMX VP-16, to create expression vectors for GST, GAL4, or VP16 fusion proteins, respectively. Full length IPAS cDNA was inserted in an inverted direction into pcDNA3, constructing an antisense IPAS expression plasmid.

Example 2: Cell Culture and Transfection Experiments

IPAS-expressing HEPA cells (Hepa IPAS cells) were established by stable transfection of mouse hepatoma Hepalcl7 cells (ATCC) with pEFIRESpuro IPAS and puromycin (5 μ g/ml) selection. In luciferase reporter gene assays, 0.5 μ g of reporter plasmid and indicated amounts of expression plasmids were used for transfection by lipofection. Conditions for hypoxia or TCDD treatment of the cells have been previously reported¹⁶. Protein expression was monitored in whole cell extracts by immunoblot assays using HIF-1 α (Novus), HLF/EPAS1 (Novus), and FLAG epitope (Sigma) antibodies essentially as previously reported^{8,22}.

IPAS mRNA expression was not detected in the wild-type cells (Fig. 3D). Under hypoxic conditions these cells showed markedly increased expression of phosphoglycerate kinase1 and VEGF mRNA expression, as expected^{11,12}. In response to hypoxia, Hepa IPAS cells showed decreased levels of hypoxia-dependent activation of these genes (45% and 48% reduction of the induction response, respectively; Fig. 3D). This IPAS-mediated effect was at the transcriptional level, since activation of a transiently transfected HRE-driven reporter gene by hypoxia was significantly lower in Hepa IPAS cells than in wild-type cells (data not shown). Reporter gene activation was even suppressed in Hepa IPAS cells following transient overexpression of HIF-1 α , indicating that IPAS impairs productive interaction between HIF-1 α and the HRE.

HRE-specific DNA binding activity by the HIF-1 α /Arnt heterodimeric complex was lower in nuclear extracts from either normoxic or hypoxic IPAS-expressing cells than in corresponding nuclear extracts from wild-type cells (Fig. 3E). The dioxin (aryl hydrocarbon) receptor which mediates gene regulation in response to xenobiotic chemicals is also a member of the bHLH/PAS transcription factor family and shares the dimerisation partner factor Arnt with HIF-1 α ¹³. In contrast to hypoxia-inducible gene expression, dioxin-induced expression of dioxin receptor target gene cytochrome P-4501A1 was not perturbed in the Hepa IPAS cells (data not shown).

Six week-old C57Bl6/J healthy mice sacrificed by a lethal dose of CO₂ and their primary corneal epithelial cells were isolated. The eyes were enucleated and the corneal tissue was dissected in DME medium supplemented with 10% bovine calf serum under a stereomicroscope. Tissue masses were placed onto a gelatin-coated tissue culture plate and incubated in the same media supplemented with 3 ng/ml human recombinant FGF- β . After incubation for 8 days, corneal epithelial cells were trypsinised, and single cell suspensions were used for subsequent assays.

Example 3: IPAS Regulation of Transcriptional Responses to Hypoxia

Due to the structural similarity of IPAS to HIFs and the colocalization of IPAS and HIF-1 α in mouse cornea the putative role of IPAS in regulation of transcriptional responses to hypoxia was investigated. A transient transfection assay was performed in HeLa cells (ATCC) using a hypoxia-response element (HRE) driven luciferase reporter gene in the absence or presence of transiently expressed IPAS. In the absence of IPAS, incubation of the cells under hypoxic (1% O₂) conditions resulted in induction of reporter gene activity, reflecting the induced transactivation function of endogenous HIFs. Transient expression of IPAS reduced this hypoxia-inducible activation response (Figs. 3A, 3B).

Hypoxia-dependent activation of the reporter gene by coexpression of either HIF-1 α (Fig. 3A) or HLF/EPAS1 (Fig. 3A) was impaired in a dose-dependent manner by IPAS. IPAS acts as a dominant negative regulator of HIF-1 α and HLF/EPAS1-mediated gene expression. IPAS had no effect on hypoxia-induced protein stabilization of HIF-1 α and HLF⁷⁻¹⁰ (Fig. 3C) indicating that IPAS targeted regulatory steps located further down-stream than protein stabilization in HIF-mediated signal

transduction.

Example 4: RNA Blot and *in situ* Hybridization Analysis

Poly(A)⁺RNA samples (4.5 µg) were collected from a variety of C57B16 mouse tissues, Hepalclc7 and Hepa IPAS cells using the guanidiumthiocyanate method. The samples were purified using oligodT (Dyna). The purified samples were analyzed by northern blot analysis using ³²P-labeled cDNA probes of mIPAS (nt 623-897), mPGK1 (nt 426-771), mVEGF3 (nt 24-466), mCYP1A1 (nt 874-1199), and mβ-actin (nt 930-1075).

The results of the analysis of mouse tissue samples demonstrated that IPAS was expressed predominantly in the eye and at lower levels in the cerebellum and the cerebrum. No expression was detected in other tested mouse tissues, indicating a tissue-restricted expression pattern of IPAS mRNA (Fig. 1C).

In situ hybridization assays of tissue samples from 8 week-old C57B16 mice were performed to characterize the spatial expression pattern of IPAS in the eye and cerebellum. The in situ hybridizations were conducted using ³⁵S-labeled mIPAS or mHIF-1α antisense RNA probes according to known methods²³.

Intense IPAS expression was observed in the epithelial cell layer of the cornea (Figs. 2A, 2B) and with lower intensity in the layers of ganglion cells, inner nuclear cells, and rods and cones of the retina (Figs. 2E, 2F). Expression of HIF-1α mRNA was detected at low levels in the epithelium of the cornea (Figs. 2C, 2D), demonstrating dominant expression of IPAS over HIF-1α in these cells. HIF-1α was also expressed in the same layers of retina where IPAS expression was observed (Figs. 2G, 2H). In the cerebellum, expression of IPAS was limited to the Purkinje cell layer (Figs. 2I, 2J). HIF-1α did not show any similar spatially defined expression throughout the sections (Figs. 2K, 2L). Both IPAS and HIF-1α mRNAs were detected as weak diffuse signals over nonspecific background levels in certain areas of the cerebrum (data not shown).

Example 5: Electrophoretic Mobility Shift and *in vitro* Protein Interaction Assays

Nuclear extracts from either normoxic or hypoxic cells were prepared and analyzed by electrophoretic mobility shift assays as known in the art¹⁶. GST-IPAS or

GAL4 fusion proteins spanning various fragments of HIF-1 α were generated by translation either in the presence or absence of ^{35}S -labeled methionine in rabbit reticulocyte lysate (Promega). Equal concentrations of ^{35}S -labeled, *in vitro* translated Arnt, HIF-1 α or IPAS were incubated with GST-IPAS or GAL4-HIF-1 α fusion proteins for 1 hour at room temperature. Afterward, the proteins were incubated with anti-GST (Amersham-Pharmacia Biotech) or anti-GAL4 (Upstate Biotechnology) antibodies coupled to Protein A-Sepharose (Amersham-Pharmacia Biotech) for 1 hour at room temperature. After brief centrifugation, coimmunoprecipitated proteins were analyzed by SDS polyacrylamide gel electrophoresis and autoradiography.

Example 6: Assays for IPAS Interaction with HIF-1 α or Arnt

Coimmunoprecipitation assays were conducted to examine whether the inhibitory action of IPAS was mediated by direct interaction with HIF-1 α or Arnt. Glutathione S-transferase- (GST-) IPAS fusion protein was coprecipitated with HIF-1 α but not with Arnt, demonstrating specific physical interaction between IPAS and HIF-1 α (Fig. 3F). The assays further demonstrated that the N-terminal structures of HIF-1 α (amino acids 1-330, mainly composed of the bHLH/PAS motif) mediated association with IPAS (Fig. 3G).

Mammalian two-hybrid assays employing a GAL4 fusion protein spanning the bHLH/PAS domain of HIF-1 α as a bait demonstrated interaction with an IPAS-VP16 fusion protein. Consistent with the *in vitro* precipitation experiments, GAL-4-IPAS failed to show any interaction with Arnt-VP16 *in vivo* (data not shown). The IPAS/HIF-1 α complex was inert with regard to binding to an HRE probe. The HRE binding activity of HIF-1 α /Arnt heterodimer was impaired upon exposure to IPAS (Fig. 3H). Both of these results are consistent with the reduced levels of HIF-1 α -dependent DNA binding activity observed in nuclear extracts of cells stably expressing IPAS (Fig. 3E).

Example 7: Investigation of Role of IPAS in Corneal Epithelium

The cornea is an interesting study target because the transparency required for clear vision is present only with total avascularity. It is known that hypoxic conditions exist in the corneal environment following overnight closure of the eye during

sleep^{14,15}. The levels of hypoxia reached in the cornea would be sufficient to stimulate HIF-1 α -dependent gene expression in other cell types. However, such a gene activation response and neovascularization of the cornea do not normally occur, suggesting a mechanism of negative regulation.

Analysis of VEGF mRNA expression in primary cultures of mouse cornea epithelium cells was conducted to ascertain whether IPAS plays such a role in negative regulation of VEGF expression in the cornea. A low but detectable level of IPAS mRNA expression under normoxic conditions was detected. Exposure of the cells to hypoxia for 24 hours resulted in enhanced IPAS mRNA expression levels (Fig. 5A).

Non-corneal mice tissues were exposed to hypoxia (6% O₂) for 6 hours to assess hypoxia-induced IPAS expression regulation. Consistent with other experimental results (Fig. 1C), very low levels of IPAS expression were observed in most tissues of control mice kept at normoxia. In addition to corneal cells, IPAS mRNA expression was induced by hypoxia (2.2- to 3.9-fold induction) in the cerebrum, cerebellum, heart, and skeletal muscle (Fig. 5B), suggesting IPAS may modulate hypoxia-inducible gene regulatory responses in these tissues under conditions of hypoxia or ischemia.

In contrast to wild-type mouse Hepalcl7 cells¹⁶, primary cornea cells were transfected with an empty expression vector and demonstrated almost undetectable basal levels of VEGF mRNA expression. Hypoxia produced only a very modest induction response (Fig. 5C).

Primary cornea cells were transiently transfected with an antisense IPAS expression vector to down-regulate IPAS expression levels. The introduction of the antisense IPAS vector resulted in elevation of basal VEGF mRNA expression levels and significant hypoxia-inducible expression of the VEGF gene (Fig. 5C), showing IPAS has an important role in negative regulation of both basal level expression and hypoxia-dependent activation of the VEGF gene in cornea epithelium.

Example 8: Mouse Corneal Micropocket Assay and Hypoxic Exposure of Mice

The mouse corneal angiogenesis assay was performed as previously reported²⁴. Slow release micropellets of sucrose aluminium sulfate and hydron polymers

containing 2.5 µg of phosphorothioate-coupled IPAS antisense (5'-TCACGCGCTG CAGCCCCAAC GCCAT-3') (SEQ ID NO:3), sense (5'-ATGGCGTTGG GGCTGCAGCG CGTGA-3') (SEQ ID NO:4), or scrambled oligonucleotides were implanted into corneal pockets of 6 week-old male C57Bl6/J mice. The full length IPAS antisense sequence is provided in SEQ ID NO:5. Alternate sequences of these or any other disclosed or claimed sequence may be employed. Alternate sequences include functional fragments and analogs, or entities having acceptable levels of homology with the specific sequence described. Construction and use of alternate sequences is known in the art.

Six mice and 12 corneas were used in each group. The vascular area of the corneas of all the mice was measured by slit-lamp stereomicroscopy on day 5 after pellet implantation, and statistically evaluated by Student's two-tailed t-test. In hypoxia experiments eight week-old mice were either kept at normoxia or exposed to normobaric hypoxia (6% O₂) for 6 hours in an airtight chamber flushed with a mixture of nitrogen and room air.

Using similar methods, an analysis of the stimulation of blood vessel growth from the limbus region was recorded five normoxic days after implantation of micropellets. Significant ($p < 0.001$ compared to sense or scrambled oligonucleotide controls) induction of neovascularization in the corneas of mice treated with the IPAS antisense oligonucleotide (Figs. 5D, 5E) was observed. The physiological conditions of hypoxia which occur in the cornea, e.g., during sleep^{14,15}, can therefore induce vascular growth upon inhibition of IPAS expression.

Example 9: Tumor Studies in Mice

Approximately 1×10^6 wild-type Hepalcl7 or stably IPAS-expressing hepatoma cells were implanted subcutaneously in an 8-10 week old male immunoincompetent SCID mouse. Six mice were in the treated group and seven mice were in the control group. Primary tumors were measured using digital calipers on the days indicated. Tumor volumes were calculated according to the formula: width² x length x 0.52 as is common in the art²⁴. At day 18 after implantation, tumor tissues were resected and fixed with 4% formalin in phosphate-buffered saline for 24 hours. Tissues were imbedded in paraffin and stained with a rat anti-mouse antibody against

CD31 antigen²⁴. Positive signals were counted under a light microscope in at least 6 random fields at 40x magnification.

The role of IPAS in negative regulation of angiogenesis was evaluated by determining both the growth rates and vascular density of the tumors formed following implantation. As shown in Fig. 4A, IPAS-expressing hepatoma cells produced tumors which showed a markedly slower growth rate than that of the wild-type cells ($p < 0.001$ - 0.01 at all time points of observation). The tumors derived from the IPAS-expressing cells showed a significantly ($p < 0.001$) reduced vascular density in comparison to the wild-type tumors, as assessed by staining tumor samples with CD31 antibodies (Figs. 4B, 4C).

Example 10: IPAS as a Pro-Angiogenic Treatment

An organism would be treated with antisense IPAS by any means appropriate and, if necessary, including any pharmaceutically acceptable carrier or adjuvant. Treatment may include such methods as topical application, injection, infusion, gene therapy, use of liposomes or controlled release mechanisms, and a variety of any and all other methods determined appropriate by the practitioner. Antisense IPAS would effectively inactivate IPAS and prevent conditional negative regulatory strategy. This would occur because IPAS would be prevented from forming a nonfunctional complex with HIF-1 α . Such a mechanism is depicted in Fig. 5F. The mechanism relied upon for the present invention and depicted in Fig. 5F resembles the mechanism of repression of the function of MyoD and related bHLH differentiation factors by Id²⁰.

Treated regions of the organism may preferably include tissues exposed to hypoxia, such as the cornea or ischemic heart tissue. Following treatment, HIF-1 α activity would no longer be suppressed and angiogenesis would proceed. Conditions that may benefit from treatment with IPAS antagonists according to the present invention include, but are not limited to, coronary heart disease, wound healing, stroke, and diabetic ulceration.

References

1. Bunn, H. F. & Poyton, R. O. Oxygen sensing and molecular adaptation to hypoxia. *Physiol Rev* 76, 839-885 (1996).
2. Wenger, R. H. Mammalian oxygen sensing, signalling and gene regulation. *J. Exp. Biol.* 203, 1253-1263 (2000).
3. Krogh, A., Brown, M., Mian, I. S., Sjolander, K. & Haussler, D. Hidden Markov models in computational biology. Applications to protein modeling. *J. Mol. Biol.* 235, 1501-1531 (1994).
4. Wang, G. L., Jiang, B. H., Rue, E. A. & Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci U S A* 92, 5510-5514 (1995).
5. Ema, M. *et al.* A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 α regulates the VEGF expression and is potentially involved in lung and vascular development. *Proc Natl Acad Sci U S A* 94, 4273-4278 (1997).
6. Tian, H., McKnight, S. L. & Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. *Genes Dev* 11, 72-82 (1997).
7. Semenza, G. L. HIF-1 and human disease: one highly involved factor. *Genes Dev* 14, 1983-1991 (2000).
8. Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y. & Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1 α by the ubiquitin-proteasome pathway. *J Biol Chem* 274, 6519-6525 (1999).
9. Maxwell, P. H. *et al.* The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [see comments]. *Nature* 399, 271-275 (1999).
10. Wiesener, M. S. *et al.* Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1 α . *Blood* 92, 2260-2268 (1998).
11. Li, H., Ko, H. P. & Whitlock, J. P. Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1 α . *J Biol Chem* 271, 21262-21267 (1996).
12. Forsythe, J. A. *et al.* Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol. Cell Biol.* 16, 4604-4613 (1996).
13. Poellinger, L. in *Inducible gene expression* (ed. Baeuerle, P. A.) 177-205 (Birkhäuser, Boston, 1995).
14. Thakur, A., Willcox, M. D. & Stapleton, F. The proinflammatory cytokines and arachidonic acid metabolites in human overnight tears: homeostatic mechanisms. *J. Clin. Immunol.* 18, 61-70 (1998).
15. Sack, R. A., Beaton, A. R. & Sathe, S. Diurnal variations in angiostatin in human tear fluid: a possible role in prevention of corneal neovascularization. *Curr. Eye. Res* 18, 186-193 (1999).
16. Gradin, K. *et al.* Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. *Mol Cell Biol* 16, 5221-5231 (1996).
17. Ravi, R. *et al.* Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1. *Genes Dev.* 14, 34-44 (2000).
18. Zundel, W. *et al.* Loss of PTEN facilitates HIF-1-mediated gene expression.

Genes Dev. 14, 391-396 (2000).

19. Li, J. *et al.* PR 39, a peptide regulator of angiogenesis. *Nat. Med.* 6, 49-55 (2000).

20. Norton, J. D., Deed, R. W., Craggs, G. & Sablitzky, F. Id helix-loop-helix protein in cell growth and differentiation. *Trends Cell Biol.* 8, 58-65 (1998).

21. Eddy, S. R. Multiple alignment using hidden Markov models. *Ismb* 3, 114-120 (1995).

22. Tanimoto, K., Makino, Y., Pereira, T., and Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1 by the von Hippel-Lindau tumor suppressor protein. *EMBO J.* 19, 4298-4309 (2000).

23. Bertilsson, G. *et al.* Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. *Proc. Natl. Acad. Sci. USA* 95, 12208-12213 (1998).

24. Cao, R. *et al.* Suppression of angiogenesis by a novel inhibitor, K1-5, generated by plasmin-mediated proteolysis. *Proc. Natl. Acad. Sci. USA* 96, 5728-5733 (1999).

WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising the sequence of SEQ ID NO:3, or active fragments or analogs thereof.
2. A pharmaceutical composition, comprising the sequence of SEQ ID NO:4, or active fragments or analogs thereof.
3. A pharmaceutical composition, comprising the sequence of SEQ ID NO:5, or active fragments or analogs thereof.
4. A pharmaceutical composition, comprising a sequence complimentary to the sequence of SEQ ID NO:1, or active fragments or analogs thereof.
5. A pharmaceutical composition, comprising a sequence having 95% homology to the sequence of SEQ ID NO:5.
6. A pharmaceutical composition, comprising a sequence having 90% homology to the sequence of SEQ ID NO:5.
7. A pharmaceutical composition, comprising a sequence having 85% homology to the sequence of SEQ ID NO:5.
8. A pharmaceutical composition, comprising a sequence having 80% homology to the sequence of SEQ ID NO:5.
9. A pharmaceutical composition, comprising a sequence having 75% homology to the sequence of SEQ ID NO:5.
10. A pharmaceutical composition, comprising a sequence having 70% homology to the sequence of SEQ ID NO:5.

11. A pharmaceutical composition according to any one of Claims 1-10, further comprising at least one item selected from the group consisting of pharmaceutical carriers, adjuvants, and diluents.
12. A method of increasing angiogenesis in a cell, a group of cells, or an organism, comprising administering a pharmaceutically effective amount of a composition according to any one of Claims 1-10 to the cell, group of cells, or organism.
13. A method of increasing HIF-1 α function in a cell, a group of cells, or an organism, comprising administering a pharmaceutically effective amount of a composition according to any one of Claims 1-10 to the cell, group of cells, or organism.
14. A method according to any one of Claims 12 and 13, wherein the cell, group of cells, or organism are under hypoxic conditions.
15. A method of treating a hypoxia-related condition in a cell, a group of cells, or an organism, comprising administering a pharmaceutically effective amount of a composition according to any one of Claims 1-10 to the cell, group of cells, or organism.
16. The method of Claim 15, wherein the hypoxia-related condition is selected from the group consisting of ischemia, coronary heart disease, wound healing, stroke, and diabetic ulceration.
17. A method of maintaining normal cell or tissue function under hypoxic conditions, comprising administering a pharmaceutical composition according to any one of Claims 1-10 to the cell or tissue.
18. A plasmid comprising the sequence of SEQ ID NO:3.
19. A plasmid comprising the sequence of SEQ ID NO:4.

20. A plasmid comprising the sequence of SEQ ID NO:5.
21. A plasmid comprising a sequence complimentary to the sequence of SEQ ID NO:1.
22. A vector comprising a plasmid according to any one of Claims 18-21.
23. A host cell transfected by a vector according to Claim 22.
24. A host cell expressing the protein encoded by any one of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

1 GGCACGAGGGCCATGGCGTTGGGGCTGCAGCGCGTGAGGTCGAACACCGA
51 GCTGCGGAAGGAGAAGTCGCGGGACGCGGCCCCGAGCCGGCGCAGCCAGG
101 AGACGGAGGTGCTGTACCAGCTGGCGCACACTCTGCCCTTTGCGCGCGGC
151 GTCAGCGCGCACCTGGACAAGGCCTCCATCATGCGCCTCACAATCAGCTA
201 CCTGCGCATGCACCGCCTCTGCGCAGCAGGTGGAAAAAGGGGGAGAGCCA
251 CTGGACGCCTGCTACCTGAAGGCCCTGGAGGGTTTCGTCATGGTACTCAC
301 CGCCGAGGGAGACATGGCTTACCTGTGCGAAAATGTCAGCAAGCACCTGG
351 GCCTCAGTCAGTGGACCTCTGTTCCCTCCCTGATACATAACCCCACTC
401 CTGGTACCAATTTCTCTCTGGAGCTCATTGGACACAGTATCTTTGATTTT
451 ATCCATCCCTGTGACCAAGAGGAACTTCAAGACGCCCTGACCCCAAGGCC
501 GAACCTGTCAAAGAAGAAGCTGGAAGCCCAACAGAGCGCCACTTTTCCC
551 TCGAATGAAGAGCACGCTCACCAGCAGAGGGCGCACGCTCAACCTCAAA
601 GCGGCCACCTGGAAGGTGCTGCACTGCTCAGGACATATGAGGGCCTACAA
651 GCCCCCTGCACAGACTTCCCCTGCCGGGAGCCCTCGCTCCGAGCCTCCCC
701 TGCAATGCCTGGTGCTTATCTGTGAAGCCATCCCCCAGCTCCCCTTCCAC
751 GATGGTGCTACTCTGGGTCTTCCACAGGAGAAGACTCCCATCTCTACCTT
801 ATCACCCCTCTTTGGAAGGCACTACTTTGTCTTGTCAAGAGGTGGCCTG
851 TTCAGGTGCTACAGGGGAAAGGGACTGAATCCTCTCTCCCCTCATGGGTG
901 TTGTGGGCCCTTAACCGGAAAAATTGTCCTGGCTAGGAGGGAGTGAAGGA
951 CATGGCCCAGCTATCCTTAGCCCAGAAACCCACAAATGTCTCCAAAACCA
1001 CCATAAAGACCTCTCCTTGTTAGGCACCAGAG

SEQUENCE LISTING

<110> MAKINO, Yuichi
CAO, Yihai
POELLINGER, Lorenz

<120> REGULATION OF HYPOXIA-INDUCIBLE GENE EXPRESSION WITH ANTISENSE
INHIBITORY PAS DOMAIN PROTEIN

<130> 056187.50678WO

<140> to be assigned

<141> 2002-11-28

<150> US 60/333,513

<151> 2001-11-28

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 307

<212> PRT

<213> Mus sp.

<220>

<221> MISC_FEATURE

<223> IPAS amino acid sequence

<400> 1

Met Ala Leu Gly Leu Gln Arg Val Arg Ser Asn Thr Glu Leu Arg Lys
1 5 10 15

Glu Lys Ser Arg Asp Ala Ala Arg Ser Arg Arg Ser Gln Glu Thr Glu
20 25 30

Val Leu Tyr Gln Leu Ala His Thr Leu Pro Phe Ala Arg Gly Val Ser
35 40 45

Ala His Leu Asp Lys Ala Ser Ile Met Arg Leu Thr Ile Ser Tyr Leu
50 55 60

Arg Met His Arg Leu Cys Ala Ala Gly Gly Lys Arg Gly Arg Ala Thr
65 70 75 80

Gly Arg Leu Leu Pro Glu Gly Pro Gly Gly Phe Arg His Gly Thr His
85 90 95

Arg Arg Gly Arg His Gly Leu Pro Val Gly Lys Cys Gln Gln Ala Pro
100 105 110

Gly Pro Gln Ser Val Asp Leu Cys Ser Ser Ser Leu Ile His Asn Pro
115 120 125

Thr Pro Gly Thr Asn Phe Ser Leu Glu Leu Ile Gly His Ser Ile Phe
130 135 140

Asp Phe Ile His Pro Cys Asp Gln Glu Glu Leu Gln Asp Ala Leu Thr
 145 150 155 160
 Pro Arg Pro Asn Leu Ser Lys Lys Lys Leu Glu Ala Pro Thr Glu Arg
 165 170 175
 His Phe Ser Leu Arg Met Lys Ser Thr Leu Thr Ser Arg Gly Arg Thr
 180 185 190
 Leu Asn Leu Lys Ala Ala Thr Trp Lys Val Leu His Cys Ser Gly His
 195 200 205
 Met Arg Ala Tyr Lys Pro Pro Ala Gln Thr Ser Pro Ala Gly Ser Pro
 210 215 220
 Arg Ser Glu Pro Pro Leu Gln Cys Leu Val Leu Ile Cys Glu Ala Ile
 225 230 235 240
 Pro Gln Leu Pro Phe His Asp Gly Ala Thr Leu Gly Leu Pro Gln Glu
 245 250 255
 Lys Thr Pro Ile Ser Thr Leu Phe Thr Pro Leu Trp Lys Ala Leu Leu
 260 265 270
 Cys Leu Val Lys Arg Trp Pro Val Gln Val Leu Gln Gly Lys Gly Thr
 275 280 285
 Glu Ser Ser Leu Pro Ser Trp Val Leu Trp Ala Leu Asn Arg Lys Asn
 290 295 300
 Cys Pro Gly
 305

<210> 2
 <211> 1032
 <212> DNA
 <213> Mus sp.

<220>
 <221> misc_feature
 <223> IPAS cDNA sequence

<400> 2
 ggcacgaggg ccatggcggt ggggctgcag cgcgtgaggt cgaacaccga gctgcggaag 60
 gagaagtcgc gggacgcggc ccgcagccgg cgcagccagg agacggaggt gctgtaccag 120
 ctggcgca ca ctctgccctt tgcgcgcggc gtcagcgcgc acctggacaa ggcctccatc 180
 atgcgcctca caatcagcta cctgcgcatg caccgcctct gcgcagcagg tggaaaaagg 240
 gggagagcca ctggacgcct gctacctgaa ggccctggag ggtttcgtca tggactcac 300
 cgccgagggg gacatggctt acctgtcgga aaatgtcagc aagcacctgg gcctcagtca 360
 gtggacctct gttcctctc cctgatacat aacccactc ctggtaccaa tttctctctg 420
 gagctcattg gacacagtat ctttgatttt atccatccct gtgaccaaga ggaacttcaa 480
 gacgccctga ccccgaggcc gaacctgtca aagaagaagc tggaagcccc aacagagcgc 540

cacttttccc tgcgaatgaa gagcacgctc accagcagag ggcgcacgct caacctcaaa 600
gcggccacct ggaaggtgct gcaactgctca ggacatatga gggcctacaa gccccctgca 660
cagacttccc ctgccgggag ccctcgctcc gagcctcccc tgcaatgcct ggtgcttata 720
tgtgaagcca tccccagct ccccttcac gatggtgcta ctctgggtct tccacaggag 780
aagactccca tctctacctt attcaccct ctttggaagg cactactttg tcttgtcaag 840
aggtggcctg ttcaggtgct acaggggaaa gggactgaat cctctctccc ctcatgggtg 900
ttgtgggccc ttaaccggaa aaattgtcct ggctaggagg gagtgaagga catggcccag 960
ctatccttag ccagaaaacc cacaaatgtc tccaaaacca ccataaagac ctctccttgt 1020
taggcaccag ag 1032

<210> 3
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Unknown

<220>
<221> misc_feature
<223> IPAS antisense DNA fragment

<400> 3
tcacgcgctg cagccccaac gccat 25

<210> 4
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Unknown

<220>
<221> misc_feature
<223> IPAS sense DNA fragment

<400> 4
atggcggttg ggctgcagcg cgtga 25

<210> 5
<211> 1032
<212> DNA
<213> Unknown

<220>
<223> Unknown

<220>
<221> misc_feature
<223> IPAS antisense DNA (full length)

<400> 5
tcggtgttcg acctcacgcg ctgcagcccc aacgccatgg ccctcgtgcc cctggctgcg 60
ccggctgctg gccgcgtccc gcgacttctc cttccgcagc gccgcgcgca aagggcagag 120
tgtgcgccag ctggtacagc acctccgtct tagctgattg tgaggcgcag gatggaggcc 180
ttgtccaggt gcgcgctgac tggctctccc cctttttcca cctgctgcgc agaggcggtg 240
catgcgcagg gtgagtacca tgacgaaacc ctccagggcc ttcaggtagc aggcgtccag 300
ccagggtgctt gctgacattt tccgacaggt aagccatgtc tccctcggcg gagtgggggt 360
atgtatcagg gaggaggaac agagggtccac tgactgaggc aaaatcaaag atactgtgtc 420
caatgagctc cagagagaaa ttggtaccag ggcctggggg tcagggcgtc ttgaagttcc 480
tcttggtcac agggatggat gggaaaagtg gcgctctgtt ggggcttcca gcttcttctt 540
tgacagggtc tttgagggtg agcgtgcgcc ctctgctggt gagcgtgctc ttcattcgca 600
ttgtaggccc tcatatgtcc tgagcagtgc agcaccttcc aggtggccgc ggggaggctc 660
ggagcgaggg ctcccggcag gggaagtctg tgcagggggc gtggaagggg agctggggga 720
tggcttcaca gataagcacc aggcattgca aaggtagaga tgggagtctt ctctgtgga 780
agaccagag tagcaccatc caggccacct cttgacaaga caaagtagtg ccttccaaag 840
aggggtgaat caccatgag gggagagagg attcagtccc tttcccctgt agcacctgaa 900
tccttcactc cctcctagcc aggacaattt ttccggttaa gggcccacaa tggttttgga 960
gacattttgt ggtttctggg ctaaggatag ctgggccatg ctctggtgcc taacaaggag 1020
aggtctttat gg 1032

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/02198

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 48/00, C12N 15/11, C07K 14/47, A61K 38/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, C12N, C07K, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 20020165140 A (ANDERS BERKENSTAM ET AL), 7 November 2002 (07.11.02), page 2, column 2, line 5 - line 18, claims 8,9	1-24
	--	
A	WO 0009657 A2 (PRESIDENT AND FELLOWS OF HARVARD COLLEGE), 24 February 2000 (24.02.00), page 1, line 34 - page 3, line 19; page 5, line 25 - page 6, line 23; page 7, line 7 - line 15, page 15, line 19 - line 23; abstract	1-24
	--	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

4 March 2003

Date of mailing of the international search report

02 -04- 2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Malin Söderman/Els

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/02198

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0074725 A1 (DANA-FARBER CANCER INSTITUTE, INC.), 14 December 2000 (14.12.00), page 4, line 22 - page 5, line 7; page 9, line 3 - page 12, line 11; page 15, line 10 - line 13, abstract --	1-24
A	WO 9856936 A1 (MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.), 17 December 1998 (17.12.98), page 11, line 17 - line 20; page 24, line 10 - line 22, abstract --	1-24
A	WO 9928469 A1 (GENZYME CORPORATION), 10 June 1999 (10.06.99), page 3, line 3 - line 24; page 29, line 11 - line 20 --	1-24
X	WO 0181581 A2 (CORIXA CORPORATION), 1 November 2001 (01.11.01), WO 0181582 & Database EMBL (on line Accession no. AAU45894 27 Feb 2002, retrieved from EBI, 100% identity in 5aa overlap with SEK NO 3	1
X	27 Feb 2002, 100% identity in 5aa overlap with SEK ID ID NO 4 --	2
P,X	WO 0202609 A1 (BIOVITRUM AB), 10 January 2002 (10.01.02), WO 200202609 A & Accession no ABK 14502 08 May 2002, retrieved from EBI 100% identity in 25 nt overlap with SEQ ID NO 3 --	1-24
P,X	J. Biol. Chem., Vol. 277, No 36, September 2002, Yuichi Makino et al: "Inhibitory PAS Domain Protein (IPAS) Is a Hypoxia-inducible Splicing Variant of the Hypoxia-inducible Factor-3 alpha Locus", pages 32405 - 32408, page 2, line 18-28, AF 481147, 14 Mar 2002, 96,296 % Identity in 54 nt overlap with SEQ ID NO 5 --	1-24

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/02198

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9928464 A2 (WISCONSIN ALUMNI RESEARCH FOUNDATION), 10 June 1999 (10.06.99), WO 9928464, page 29, line 13-19, AAX 58986, 23 Aug 1999, 79, 7751 identity in 89 nt overlap with SEQ ID NO 5, 76, 316% identity in 304aa overlap with SEQ ID NO 1	9,10
A	Acc no AAX50986 --	1-8,11-24
A	WO 9928464 A2 (WISCONSIN ALUMNI RESEARCH FOUNDATION), 10 June 1999 (10.06.99), AAY06295, 23 Aug 1999	1-8,11-24
X	76.596% identity in 235 aa overlap with SEQ ID NO 1 --	9-10
P,X	Nature, volume 414 (6863) 2001, Makino Y. et al: "Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression", pages 550-554, AF 416641, 11 Dec 2001, 79,775 % identity in 89 nt overlap with SEQ ID NO 5, Acnr AF416641, 11 Dec 2001, 100% ID in 307aa overlap with SEQ ID NO 1, Accnr Q8VHRI, 1 Mar 2002, 100% identity in 307 aa overlap SEQ 10 No 1 --	1-24
P,X	Artikel ref, Accession nr AF416641, 11 Dec 2001, 100 % identity in 25 nt overlap with SEQ ID NO 3. --	1-24
A	Database Acc No AA028416, 100 % ID in 51 nt overlap with SEQ No 5, 17 Aug 1996, - Database Acc No A1322407, 29 Dec 1998, 100 % ID In 25 nt overlap with SEQ ID No 3 - Acc No AI 322401, 29 Dec 1998, 100 % identity in 25 nt overlap with SEQ ID NO 4 AI 322407, 29 Dec 1998, 100 % identity in 152 aa overlap with SEQ ID No 1 --	1-24

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/02198

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Q 9RQ54, May 2000, 76.596 % identity in 235 an overlap with SEQ ID NO 1 AF 079143, 02 Jan 2000, 100% identity in 50 nt overlap with SEQ ID NO 5 --	1-24
X	WO 0159063 A2 (HUMAN GENOME SCIENCES, INC.), 16 August 2001 (16.08.01), ABA-14358, 23 Jan 2002, 92,727 % identity in 55 nt overlap with SEQ ID NO 5 --	6-10
P,X	WO 0202609 A1 (BIOVITRUM AB), 10 January 2002 (10.01.02) --	1-24
P,X	WO 200202609 A & Accession no ABK 14502 08 May 2002, retrieved from EBI, 100% identity in 25 nt overlap with SEQ ID NO 4 Acc no: AAU 75902, 8 May 2002 100% identity in 307 aa overlap with SEQ ID NO 1 Acc no: ABK 14502, 8 May 2002 100% identity in 307 aa overlap with SEQ ID NO 1 Acc no: ABK 14501, 8 May 2002 100% identity with SEQ ID NO 5 -- -----	1-24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE02/02198

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **12-15, 17**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE02/02198

Claims 12-15,17 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/SE 02/02198

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 20020165140 A	07/11/02	NONE	
WO 0009657 A2	24/02/00	AU 5562999 A US 6395548 B WO 0010096 A	06/03/00 28/05/02 24/02/00
WO 0074725 A1	14/12/00	EP 1198255 A	24/04/02
WO 9856936 A1	17/12/98	AU 8536998 A EP 0990042 A	30/12/98 05/04/00
WO 9928469 A1	10/06/99	AU 749467 B AU 1626899 A CA 2311643 A EP 1034267 A IL 136454 D JP 2001525173 T NO 20002849 A US 6432927 B US 6274585 B	27/06/02 16/06/99 10/06/99 13/09/00 00/00/00 11/12/01 02/08/00 13/08/02 14/08/01
WO 0181581 A2	01/11/01	AU 5552401 A EP 1278854 A	07/11/01 29/01/03
WO 0202609 A1	10/01/02	AU 2418001 A AU 7477201 A SE 0002551 D US 2002165140 A	25/06/01 14/01/02 00/00/00 07/11/02
WO 9928464 A2	10/06/99	AU 1610499 A	16/06/99
WO 9928464 A2	10/06/99	AU 1610499 A	16/06/99

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/SE 02/02198

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0159063 A2	16/08/01	AU 2950801 A	07/08/01
		AU 3095801 A	07/08/01
		AU 3645901 A	07/08/01
		AU 3646001 A	07/08/01
		AU 3646101 A	07/08/01
		AU 3646201 A	07/08/01
		AU 3646301 A	07/08/01
		AU 3646401 A	07/08/01
		AU 3646501 A	07/08/01
		AU 3646601 A	07/08/01
		AU 3794301 A	07/08/01
		AU 3794401 A	07/08/01
		AU 3794701 A	07/08/01
		AU 3794901 A	07/08/01
		AU 3795001 A	07/08/01
		AU 3795101 A	07/08/01
		AU 3795201 A	07/08/01
		AU 3795301 A	07/08/01
		AU 3795401 A	07/08/01
		AU 3795501 A	07/08/01
		AU 3795701 A	07/08/01
		AU 3795801 A	07/08/01
		AU 3972601 A	07/08/01
		AU 3972701 A	07/08/01
		AU 3972801 A	07/08/01
		AU 4140201 A	07/08/01
		AU 4140301 A	07/08/01
		AU 4140401 A	07/08/01
		AU 4140501 A	07/08/01
		AU 4140601 A	07/08/01
		AU 4140701 A	07/08/01
		AU 4140801 A	07/08/01
		AU 4140901 A	07/08/01
		AU 4141001 A	07/08/01
		AU 4141101 A	20/08/01
		AU 4141201 A	07/08/01
		AU 4141301 A	07/08/01
		AU 4141401 A	07/08/01
		AU 4141501 A	07/08/01
		AU 4141601 A	07/08/01
		AU 4141701 A	07/08/01
		AU 4141801 A	07/08/01
		AU 4141901 A	07/08/01
		AU 4313401 A	07/08/01
		AU 4313501 A	07/08/01
		AU 4313601 A	07/08/01
		AU 4313701 A	14/08/01
		AU 4526201 A	07/08/01
		AU 4719001 A	07/08/01
		AU 4719101 A	07/08/01
		AU 4905201 A	07/08/01
		AU 4905301 A	07/08/01
		AU 4905401 A	07/08/01
		AU 5076701 A	07/08/01
		AU 5076801 A	07/08/01

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/SE 02/02198

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0159063 A2	16/08/01	AU 5076901 A	07/08/01
		AU 5077001 A	07/08/01
		AU 5077101 A	20/08/01
		AU 5077201 A	07/08/01
		AU 5287801 A	07/08/01
		AU 5287901 A	07/08/01
		AU 5516201 A	07/08/01
		AU 5791201 A	07/08/01
		AU 6096901 A	07/08/01
		AU 6289901 A	18/10/01
		EP 1251863 A	30/10/02
		EP 1252176 A	30/10/02
		EP 1252185 A	30/10/02
		EP 1252289 A	30/10/02
		EP 1252290 A	30/10/02
		EP 1252297 A	30/10/02
		EP 1252302 A	30/10/02
		EP 1252303 A	30/10/02
		EP 1252312 A	30/10/02
		EP 1252326 A	30/10/02
		EP 1252337 A	30/10/02
		EP 1254147 A	06/11/02
		EP 1254148 A	06/11/02
		EP 1254150 A	06/11/02
		EP 1254151 A	06/11/02
		EP 1254152 A	06/11/02
		EP 1254153 A	06/11/02
		EP 1254154 A	06/11/02
		EP 1254157 A	06/11/02
		EP 1254165 A	06/11/02
		EP 1254170 A	06/11/02
		EP 1254171 A	06/11/02
		EP 1254172 A	06/11/02
		EP 1254173 A	06/11/02
		EP 1254217 A	06/11/02
		EP 1254218 A	06/11/02
		EP 1254219 A	06/11/02
		EP 1254228 A	06/11/02
		EP 1254242 A	06/11/02
		EP 1254248 A	06/11/02
		EP 1254272 A	06/11/02
		EP 1255766 A	13/11/02
		EP 1255767 A	13/11/02
		EP 1255768 A	13/11/02
		EP 1255776 A	13/11/02
		EP 1255777 A	13/11/02
		EP 1255778 A	13/11/02
		EP 1255817 A	13/11/02
		EP 1255864 A	13/11/02
		EP 1255869 A	13/11/02
		EP 1259526 A	27/11/02
		EP 1259528 A	27/11/02
		EP 1259531 A	27/11/02
		EP 1259540 A	27/11/02
		EP 1259642 A	27/11/02

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/SE 02/02198

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0159063 A2	16/08/01	EP 1261380 A	04/12/02
		EP 1261618 A	04/12/02
		EP 1261619 A	04/12/02
		EP 1261633 A	04/12/02
		EP 1261634 A	04/12/02
		EP 1261637 A	04/12/02
		EP 1261703 A	04/12/02
		EP 1261742 A	04/12/02
		EP 1261745 A	04/12/02
		EP 1263944 A	11/12/02
		EP 1265910 A	18/12/02
		EP 1268527 A	02/01/03
		US 2002042096 A	11/04/02
		US 2002042386 A	11/04/02
		US 2002061521 A	23/05/02
		US 2002077270 A	20/06/02
		US 2002086330 A	04/07/02
		US 2002086353 A	04/07/02
		US 2002086811 A	04/07/02
		US 2002086820 A	04/07/02
		US 2002086821 A	04/07/02
		US 2002086822 A	04/07/02
		US 2002086823 A	04/07/02
		US 2002090615 A	11/07/02
		US 2002090672 A	11/07/02
		US 2002090673 A	11/07/02
		US 2002090674 A	11/07/02
		US 2002094953 A	18/07/02
		US 2002102638 A	01/08/02
		US 2002119919 A	29/08/02
		US 2002120103 A	29/08/02
		US 2002132753 A	19/09/02
		US 2002132767 A	19/09/02
		US 2002147140 A	10/10/02
		US 2002151479 A	17/10/02
		US 2002161208 A	31/10/02
		US 2002164685 A	07/11/02
		US 2002165137 A	07/11/02
		US 2002168711 A	14/11/02
		US 2002173454 A	21/11/02
		US 2003013649 A	16/01/03
		WO 0154472 A	02/08/01
		WO 0154473 A	02/08/01
		WO 0154474 A	02/08/01
		WO 0154708 A	02/08/01
		WO 0154733 A	02/08/01
		WO 0155162 A	02/08/01
		WO 0155163 A	02/08/01
		WO 0155164 A	02/08/01
		WO 0155167 A	02/08/01
		WO 0155168 A	02/08/01
		WO 0155173 A	02/08/01
		WO 0155200 A	02/08/01
		WO 0155201 A	02/08/01
		WO 0155202 A	02/08/01

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/SE 02/02198

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0159063 A2	16/08/01	WO 0155203 A	02/08/01
		WO 0155204 A	02/08/01
		WO 0155205 A	02/08/01
		WO 0155206 A	02/08/01
		WO 0155207 A	02/08/01
		WO 0155208 A	02/08/01
		WO 0155300 A	02/08/01
		WO 0155301 A	02/08/01
		WO 0155302 A	02/08/01
		WO 0155303 A	02/08/01
		WO 0155304 A	02/08/01
		WO 0155305 A	02/08/01
		WO 0155306 A	02/08/01
		WO 0155307 A	02/08/01
		WO 0155308 A	02/08/01
		WO 0155309 A	02/08/01
		WO 0155310 A	02/08/01
		WO 0155311 A	02/08/01
		WO 0155312 A	02/08/01
		WO 0155313 A	02/08/01
		WO 0155314 A	02/08/01
		WO 0155315 A	02/08/01
		WO 0155316 A	02/08/01
		WO 0155317 A,B	02/08/01
		WO 0155318 A	02/08/01
		WO 0155319 A	02/08/01
		WO 0155320 A	02/08/01
		WO 0155321 A	02/08/01
		WO 0155322 A	02/08/01
		WO 0155323 A	02/08/01
		WO 0155324 A	02/08/01
		WO 0155325 A	02/08/01
		WO 0155326 A	02/08/01
		WO 0155327 A	02/08/01
		WO 0155328 A	02/08/01
		WO 0155329 A	02/08/01
		WO 0155343 A	02/08/01
		WO 0155350 A	02/08/01
		WO 0155355 A	02/08/01
		WO 0155364 A	02/08/01
		WO 0155367 A	02/08/01
		WO 0155368 A	02/08/01
		WO 0155387 A	02/08/01
		WO 0155388 A	02/08/01
		WO 0155430 A	02/08/01
		WO 0155440 A	02/08/01
		WO 0155441 A	02/08/01
		WO 0155447 A	02/08/01
		WO 0155448 A	02/08/01
		WO 0155449 A	02/08/01
		WO 0157182 A	09/08/01
		WO 0159064 A	16/08/01
		AU 3858501 A	03/09/01
		EP 1261635 A	04/12/02
		US 2002151009 A	17/10/02

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/12/02

International application No.

PCT/SE 02/02198

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0159063	A2	16/08/01	WO	0162789 A	30/08/01
				AU	4535401 A	12/09/01
				EP	1259525 A	27/11/02
				US	2002160493 A	31/10/02
				WO	0164703 A	07/09/01
				AU	5291701 A	03/10/01
				EP	1268541 A	02/01/03
				WO	0170804 A	27/09/01
				AU	5332301 A	30/10/01
				US	2002106780 A	08/08/02
				WO	0179253 A	25/10/01
				AU	7488801 A	03/12/01
				WO	0190304 A	29/11/01
				AU	6678701 A	08/01/02
				WO	0200677 A,B	03/01/02
				AU	3644501 A	07/08/01
				AU	7171401 A	14/01/02
				WO	0202587 A	10/01/02
				US	2002045230 A	18/04/02
<hr/>						
WO	0202609	A1	10/01/02	AU	2418001 A	25/06/01
				AU	7477201 A	14/01/02
				SE	0002551 D	00/00/00
				US	2002165140 A	07/11/02
<hr/>						

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.